GRDN

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will release second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call to discuss the results at 4:30 p.m. Eastern Time. Conference Call Details The conference call will be available via audio webcast at https://investors.guardianpharmacy.com and can also be accessed by dialing +1 (833) 461-5787 for participants located in the United.

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) has acquired Wellness Concepts, a long-term care pharmacy based in Grottoes, Virginia.

Do you have more faith in DuPont analysis than in simple ROE calculation? Tap CASY, ECG, GRDN, EXPD and MAMA for gains.

Guardian Pharmacy (GRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that Kendall Forbes, who has served as Executive Vice President of Sales & Operations since 2004, has decided to retire, effective as of July 1, 2026. Upon Mr. Forbes's retirement, David Morris, currently Executive Vice President and Chief Financial Officer of Guardian will assume the role of Chief Operating Officer. In connection with Mr. Morris' new role, Will Mudd, Senior Vice President, Finance, has b.

Guardian Pharmacy (GRDN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Guardian Pharmacy Services, Inc. (GRDN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Guardian Pharmacy Services (GRDN) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.21 per share a year ago.

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.